摘要: |
抗程序性死亡受体1(PD-1)及其配体(PD-L1)抗体已应用于临床多种肿瘤的治疗,在晚期胆道癌(biliary tract cancer,BTC)也取得显著疗效,但同时也有导致多种不良反应(adverse effects,AEs),如皮疹、腹泻及肝功能损伤等。本文对抗PD-1/PD-L1抗体单药及联药治疗BTC的疗效、相关AEs及管理对策作一综述。 |
关键词: 胆道肿瘤 免疫检查点抑制剂 不良反应 管理 |
DOI:10.12025/j.issn.1008-6358.2022.20220849 |
分类号:R735.8 |
基金项目:国家自然科学基金(82073272). |
|
The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer |
MA Jing, HU Bo, YANG Zhang-fu, XU Yang
|
Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute of Fudan University, Shanghai 200032, China
|
Abstract: |
Anti-programmed death receptor 1 (PD-1) and its ligand (PD-L1) antibodies have been applied in the clinical treatment of a variety of tumors, including advanced biliary tract cancer (BTC), and have achieved significant efficacy. Meanwhile, PD-1/PD-L1 antibodies also result in many adverse effects (AEs), such as rush, diarrhea, liver dysfunction and so on. This paper briefly reviews efficacy and AEs of anti-PD-1/PD-L1 antibodies monotherapy and combination therapy in BTC, and tries to formulate strategies of AEs management. |
Key words: biliary tract neoplasms immune checkpoint inhibitors adverse events management |